Compare ESP & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | ASRT |
|---|---|---|
| Founded | 1928 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 75.1M |
| IPO Year | N/A | 1997 |
| Metric | ESP | ASRT |
|---|---|---|
| Price | $42.95 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 15.7K | ★ 313.9K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | $42,600,530.00 | ★ $137,354,000.00 |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $13.60 | ★ N/A |
| Revenue Growth | 4.90 | ★ 9.22 |
| 52 Week Low | $24.85 | $0.51 |
| 52 Week High | $55.00 | $1.01 |
| Indicator | ESP | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 41.47 |
| Support Level | $42.04 | $0.75 |
| Resistance Level | $44.33 | $0.80 |
| Average True Range (ATR) | 1.81 | 0.04 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 63.52 | 23.22 |
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.